Free Trial
→ New President Kamala warning (From Stansberry Research) (Ad)

10 Best Small Cap Stocks to Buy Now - 4 of 10

Slide 4
Back to 3
Continue to 5
 
Back to 3
Continue to 5
 

Oruka Therapeutics (NASDAQ:ORKA)

Consensus Rating
Buy
Rating Score
3.3
Ratings Breakdown
6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$41.25 (68.9% Upside)

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/17/2024Leerink PartnrsUpgradeStrong-Buy
9/17/2024Leerink PartnersInitiated CoverageOutperform$44.00
9/16/2024Lifesci CapitalInitiated CoverageOutperform$41.00
9/16/2024TD CowenInitiated CoverageBuy
9/13/2024Jefferies Financial GroupInitiated CoverageBuy$40.00
9/4/2024WedbushInitiated CoverageOutperform$40.00
9/3/2024WedbushUpgradeStrong-Buy
Slide 4
Back to 3
Continue to 5
 

Our #1 Ticker for the Rare "Retirement Window" (Ad)

We've only seen this happen three times in the past 20 years... And every time - like clockwork - it's minted an entire new class of millionaires.

Click here for our #1 "Retirement Window" Stock >>>

More From MarketBeat
Biden’s Capital Gains Tax to Devastate Savings!
Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...
Golden Crest | Sponsored
7 Oversold Stocks That are Ready to Rally
Buy low and sell high. It's easy to understand, but it's a strategy that can be difficult to execute for even ...
MarketBeat
New President Kamala warning
Financial nightmare coming after election In 2018, one independent research predicted Kamala Harris was on ...
Stansberry Research | Sponsored
7 Dividend Aristocrats to Buy After Earnings
During earnings season, analysts talk about earnings growth — and for good reason. Nothing drives stock ...
MarketBeat
Biden's Executive Order, Dems Digital Money Legislation, First Step To
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...
Monetary Gold | Sponsored
7 Stocks Under $20 You Won’t Want to Miss
The price of a stock and the value of that stock are frequently different. And many investors have learned the...
MarketBeat